Literature DB >> 24488687

Preoperative findings, pathological stage PSA recurrence in men with prostate cancer incidentally detected at radical cystectomy: our experience in 242 cases.

Pietro Pepe1, Filippo Fraggetta, Antonio Galia, Paolo Panella, Michele Pennisi, Maurizio Colecchia, Francesco Aragona.   

Abstract

PURPOSE: Preoperative findings, pathological stage PSA recurrence in patients with prostate cancer incidentally detected (iPCa) at radical cystectomy (RCP) were prospectively evaluated.
METHODS: From July 2000 to July 2013, 242 men 71 years old (median) underwent RCP; preoperatively, all patients underwent digital rectal examination (DRE), total and free/total PSA. The bladder was totally examined; moreover, the prostate gland was step-sectioned at 4-mm intervals. The incidence of iPCa that fulfilled criteria for clinically significant iPCa was recorded: tumor volume ≥0.5 mL, Gleason grade ≥4, extracapsular extension, seminal vesicle invasion, lymph node metastasis or positive surgical margins. In the presence of iPCa, the patients underwent PSA evaluation during the follow-up and recurrence was defined as two subsequent rises >0.2 ng/mL.
RESULTS: Among the 50 (20.6%) out of 242 patients submitted to RCP, an iPCa was found and 18 (36%) of them met criteria for insignificant iPCa; moreover, 30% of the patients had apex involvement. Median total PSA and PSA F/T values were not significantly different in the presence versus the absence of iPCa (2.6 vs 2.7 ng/mL and 26 vs 27%; p > 0.05) and between significant versus insignificant iPCa (p > 0.05). None of the patients during the follow-up (median 58 months; range 6-102 months) had PSA recurrence.
CONCLUSIONS: PSA and PSA F/T values are provided for poor accuracy in distinguishing preoperatively significant from insignificant iPCa; however, the life expectancy of the patients is dramatically influenced by bladder cancer pTN (in our series, none developed PSA failure). In younger men in whom a prostate-sparing cystectomy could be proposed, an accurate preoperative evaluation should be mandatory to rule out significant iPCa at the risk of apex involvement (in our series equal to 30% of the cases).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488687     DOI: 10.1007/s11255-014-0647-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  26 in total

1.  Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study.

Authors:  L Cindolo; G Benincasa; R Autorino; S Domizio; G De Rosa; G Testa; M D'Armiento; V Altieri
Journal:  Oncol Rep       Date:  2001 Mar-Apr       Impact factor: 3.906

Review 2.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

3.  The incidence and relevance of prostate cancer in radical cystoprostatectomy specimens.

Authors:  M Alsinnawi; B Loftus; R Flynn; T McDermott; R Grainger; J A Thornhill
Journal:  Int Urol Nephrol       Date:  2012-07-07       Impact factor: 2.370

4.  Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens.

Authors:  Mazen Abdelhady; Ashraf Abusamra; Stephen E Pautler; Joseph L Chin; Jonathan I Izawa
Journal:  BJU Int       Date:  2006-10-09       Impact factor: 5.588

5.  Incidentally detected prostate cancer in cystoprostatectomy specimens.

Authors:  C Kouriefs; T Fazili; S Masood; M S Naseem; G R Mufti
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

6.  Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?

Authors:  Roberta Mazzucchelli; Francesca Barbisan; Marina Scarpelli; Antonio Lopez-Beltran; Theodorus H van der Kwast; Liang Cheng; Rodolfo Montironi
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

7.  Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer.

Authors:  Renzo Colombo; Roberto Bertini; Andrea Salonia; Richard Naspro; Massimo Ghezzi; Bruno Mazzoccoli; Federico Deho'; Francesco Montorsi; Patrizio Rigatti
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

8.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function.

Authors:  Hugo H Davila; Timothy Weber; David Burday; Scott Thurman; Rafael Carrion; Raoul Salup; Jorge L Lockhart
Journal:  BJU Int       Date:  2007-09-14       Impact factor: 5.588

10.  Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series.

Authors:  Pierre Nevoux; Adil Ouzzane; Hashim U Ahmed; Mark Emberton; Rodolfo Montironi; Joseph C Presti; Arnauld Villers
Journal:  BJU Int       Date:  2011-12-22       Impact factor: 5.588

View more
  4 in total

1.  Evaluation of the residual prostate cancer rate on cystoprostatectomy specimen in patients treated with radiotherapy for prostate cancer.

Authors:  Jeanne Schlegel; Charles Chahwan; Khelifa Ait Said; Lionel Vaudreuil; Sofiane Seddik; Xavier Tillou
Journal:  Int Urol Nephrol       Date:  2019-10-18       Impact factor: 2.370

Review 2.  Concomitant bladder cancer and prostate cancer: challenges and controversies.

Authors:  Antonio Lopez-Beltran; Liang Cheng; Francesco Montorsi; Maria Scarpelli; Maria R Raspollini; Rodolfo Montironi
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

3.  Concomitant Gleason Score ≥ 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy.

Authors:  Christian Thomas; Alexander Giesswein; Michael Hainz; Raimund Stein; Peter Rubenwolf; Frederik C Roos; Andreas Neisius; Sebastian Nestler; Christian Hampel; Wolfgang Jäger; Christoph Wiesner; Joachim W Thüroff
Journal:  Int Urol Nephrol       Date:  2015-09-16       Impact factor: 2.370

Review 4.  Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.

Authors:  Jörgen Elgqvist
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.